Loading...
•
Mar 31, 2023
RAPT Q1 2023 Earnings Report
RAPT Therapeutics reported financial results for the first quarter ended March 31, 2023.
Key Takeaways
RAPT Therapeutics reported a net loss of $29.3 million for the first quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $231.6 million as of March 31, 2023, expected to support operations through mid-2025.
Expanded RPT193 program with the initiation of a Phase 2a clinical trial in asthma.
Continued enrollment in Phase 2b trial of RPT193 in atopic dermatitis, with top line data expected in mid-2024.
Continued enrollment in Phase 2 trial of FLX475 in multiple cancer indications, with an update anticipated in the second half of this year.
Maintained a strong cash position of $231.6 million, expected to support operations through mid-2025.
Forward Guidance
The company is focused on advancing its two lead programs, RPT193 and FLX475. The company's cash position is expected to support operations through mid-2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...